Pharmacokinetics of isoniazid in low-birth-weight and premature infants

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2229-2234

  Bekker, A ^a,b   Schaaf, H S ^a,b   Seifart, H I ^a   Draper, H R ^b   Werely, C J ^a   Cotton, M F ^a   Hesseling, A C ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALANINE AMINOTRANSFERASE; ARYLAMINE ACETYLTRANSFERASE; ARYLAMINE N ACETYLTRANSFERASE 2; COTRIMOXAZOLE; ETHIONAMIDE; HYDROCHLOROTHIAZIDE; ISONIAZID; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PYRAZINAMIDE; RIFAMPICIN; SPIRONOLACTONE; THEOPHYLLINE; UNCLASSIFIED DRUG;

ACETYLATION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; GENOTYPE; GESTATIONAL AGE; HETEROZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LOW BIRTH WEIGHT; MALE; PLASMA CONCENTRATION-TIME CURVE; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; FEMALE; GENOTYPE; HUMANS; INFANT, LOW BIRTH WEIGHT; INFANT, NEWBORN; ISONIAZID; MALE; PROSPECTIVE STUDIES; TUBERCULOSIS;

EID: 84896982535     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01532-13     Document Type: Article

References (37)

1. Pillay T, Khan M, Moodley J, Adhikari M, Padayatchi N, Naicker V, Pillay DG, Coovadia HM. 2001. The increasing burden of tuberculosis in pregnant women, newborns and infants under 6 months of age in Durban, KwaZulu-Natal. S. Afr. Med. J. 91:983-987. (Pubitemid 34041123)
2. Jana N, Vasishta K, Jindal SK, Khunnu B, Ghosh K. 1994. Perinatal outcome in pregnancies complicated by pulmonary tuberculosis. Int. J. Gynaecol. Obstet. 44:119-124. http://dx.doi.org/10.1016/0020-7292(94)90064-7. (Pubitemid 24060078)
3. Siza JE. 2008. Risk factors associated with low birth weight of neonates among pregnant women attending a referral hospital in northern Tanzania. Tanzan. J. Health Res. 10:1-8.
4. Figueroa-Damián R, Arredondo-García JL. 2001. Neonatal outcome of children born to women with tuberculosis. Arch. Med. Res. 32:66-69. http://dx.doi.org/10.1016/S0188-4409(00)00266-6. (Pubitemid 32229913)
5. World Health Organization. 2006. Guidance for national tuberculosis programmes on the management of tuberculosis in children. WHO/HTM/TB/2006.371. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/ 2006/WHO-HTM-TB-2006.371-eng.pdf.
6. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, Enarson DA, Donald PR, Beyers N. 2004. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int. J. Tuberc. Lung Dis. 8:392-402. (Pubitemid 38624845)
7. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. 2000. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst. Rev. 2000:CD001363. http://dx.doi.org/10.1002/14651858.CD001363.
8. Evans DA, Manley KA, McKusick VA. 1960. Genetic control of isoniazid metabolism in man. Br. Med. J. 2:485-491. http://dx.doi.org/10.1136/bmj.2.5197. 485.
9. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349:1157-1167. http://dx.doi.org/10.1056/ NEJMra035092. (Pubitemid 37122329)
10. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. 2006. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin. Pharmacokinet. 45:1077-1097. http://dx.doi.org/10.2165/00003088-200645110-00003. (Pubitemid 44631388)
11. Wood R, Lawn SD, Johnstone-Robertson S, Bekker LG. 2011. Tuberculosis control has failed in South Africa-time to reappraise strategy. S. Afr. Med. J. 101:111-114.
12. Department of Health, South Africa. 2010. National antenatal sentinel HIV and syphilis prevalence survey in South Africa, 2009. Department of Health, Pretoria, South Africa.
13. Department of Health, South Africa. 2009. National tuberculosis management guidelines, 2009. Department of Health, Pretoria, South Africa. http://familymedicine.ukzn.ac.za/Libraries/Guidelines-Protocols/ TB-Guidelines-2009.sflb.ashx.
14. South African National AIDS Council, National Department of Health, South Africa. 2010. Clinical guidelines: PMTCT (prevention of mother-to-child transmission). National Department of Health, South Africa, Pretoria, South Africa. http://www.fidssa.co.za/images/PMTCT-Guidelines.pdf.
15. National Institute of Allergy and Infectious Diseases. 2007. Division of Microbiology and Infectious Diseases (DMID) pediatric toxicity tables. National Institutes of Health, Bethesda, MD. http://www.niaid.nih.gov/LabsAndResources/ resources/DMIDClinRsrch/Documents/dmidpedtox.pdf.
16. Seifart HI, Gent WL, Parkin DP, van Jaarsveld PP, Donald PR. 1995. High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J. Chromatogr. B Biomed. Appl. 674:269-275. http://dx.doi.org/10.1016/0378-4347(96)82886-6. (Pubitemid 26005467)
17. Miller SA, Dykes DD, Polesky HF. 1988. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16: 1215. http://dx.doi.org/10.1093/nar/16.3.1215.
18. Parkin DP, Vandenplas S, Botha FJ, Vandenplas ML, Seifart HI, van Helden PD, van der Walt BJ, Donald PR, van Jaarsveld PP. 1997. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am. J. Respir. Crit. Care Med. 155:1717-1722. http://dx.doi.org/10.1164/ajrccm.155.5. 9154882. (Pubitemid 27216683)
19. Vatsis KP, Weber WW, Bell DA, Dupret JM, Evans DA, Grant DM, Hein DW, Lin HJ, Meyer UA, Relling MV, Sim E, Suzuki T, Yamazoe Y. 1995. Nomenclature for N-acetyltransferases. Pharmacogenetics 5:1-17. http://dx.doi.org/10.1097/ 00008571-199502000-00001.
20. Peloquin CA. 1992. Therapeutic drug monitoring: principles and applications in mycobacterial infections. Drug Ther. 22:31-36.
21. Vivien JN, Thibier R, Grosset J, Lepeuple A. 1958. Early results of isoniazid therapy as a function of the active blood level of isoniazid; study of 100 cases. Rev. Tuberc. 22:208-222. (Article in French.)
22. Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, Sirgel FA, Venter A, Maritz JS. 2007. The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur. J. Clin. Pharmacol. 63: 633-639. http://dx.doi.org/10.1007/s00228-007-0305-5. (Pubitemid 46911342)
23. World Health Organization. 2009. Dosing instructions for the use of currently available fixed-dose combination TB medicines for children. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/challenges/ interim-paediatric-fdc-dosing-instructions-sept09.pdf. Accessed June 2013.
24. Peloquin CA, Namdar R, Dodge AA, Nix DE. 1999. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int. J. Tuberc. Lung Dis. 3:703-710. (Pubitemid 29378471)
25. Höglund P, Nilsson LG, Paulsen O. 1987. Interaction between isoniazid and theophylline. Eur. J. Respir. Dis. 70:110-116. (Pubitemid 17015736)
26. Decloedt EH, Mwansa-Kambafwile J, van der Walt JS, McIlleron H, Denti P, Smith P, Wiesner L, Ranqaka M, Wilkinson RJ, Maartens G. 2013. The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals. Int. J. Tuberc. Lung Dis. 17:333-335. http://dx.doi.org/10.5588/ijtld.12.0427.
27. Miceli JN, Olson WA, Cohen SN. 1981. Elimination kinetics of isoniazid in the newborn infant. Dev. Pharmacol. Ther. 2:235-239. (Pubitemid 11127748)
28. Rey E, Gendrel D, Treluyer JM, Tran A, Pariente-Khayat A, d'Athis P, Pons G. 2001. Isoniazid pharmacokinetics in children according to acetylator phenotype. Fundam. Clin. Pharmacol. 15:355-359. http://dx.doi.org/10.1046/j. 1472-8206.2001.00044.x. (Pubitemid 34037826)
29. Piñeiro-Carrero VM, Piñeiro EO. 2004. Liver. Pediatrics. 113(Suppl 4):1097-1106. (Pubitemid 38437364)
30. Kearns GL. 2000. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J. Allergy Clin. Immunol. 106(Suppl 3):S128-S138. http://dx.doi.org/10.1067/mai.2000.109419. (Pubitemid 32015205)
31. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. 1999. Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Pharmacokinet. 36:439-452. http://dx.doi.org/10.2165/00003088-199936060-00005. (Pubitemid 29317491)
32. Tran JH, Montakantikul P. 1998. The safety of antituberculosis medications during breastfeeding. J. Hum. Lact. 14:337-340. http://dx.doi.org/ 10.1177/089033449801400427. (Pubitemid 128504485)
33. Ramachandran G, Hemanth Kumar AK, Bhavani PK, Poorana Gangadevi N, Sekar L, Vijayasekaran D, Banu Rekha VV, Ramesh Kumar S, Ravichandran N, Mathevan G, Swaminathan S. 2013. Age, nutritional status and INH acetylator status affect pharmacokinetics of antituberculosis drugs in children. Int. J. Tuberc. Lung Dis. 17:800-806. http://dx.doi.org/10.5588/ijtld.12.0628.
34. Zhu R, Kiser JJ, Seifart HI, Werely CJ, Mitchell CD, D'Argenio DZ, Fletcher CV. 2012. The pharmacogenetics of NAT2 enzyme maturation in perinatally HIV exposed infants receiving isoniazid. J. Clin. Pharmacol. 52:511-519. http://dx.doi.org/10.1177/0091270011402826.
35. Dieu MJ. 1972. Role of isoniazid in hepatotoxicity with the INH-rifampicin combination in tuberculosis in children. J. Med. Lyon 53: 1323-1324 passim. (Article in French.)
36. Tsagaropoulou-Stinga H, Mataki-Emmanouilidou T, Karida-Kavalioti S, Manios S. 1985. Hepatotoxic reactions in children with severe tuberculosis treated with isoniazid-rifampin. Pediatr. Infect. Dis. 4:270-273. http://dx.doi.org/10.1097/00006454-198505000-00013. (Pubitemid 15093171)
37. Thee S, Seddon JA, Donald PR, Seifart HI, Werely CJ, Hesseling AC, Rosenkranz B, Roll S, Magdorf K, Schaaf HS. 2011. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob. Agents Chemother. 55:5560-5567. http://dx.doi.org/10.1128/AAC.05429-11.